TWI532843B - 與癌症有關之基因或分子變異之檢測 - Google Patents
與癌症有關之基因或分子變異之檢測 Download PDFInfo
- Publication number
- TWI532843B TWI532843B TW100144098A TW100144098A TWI532843B TW I532843 B TWI532843 B TW I532843B TW 100144098 A TW100144098 A TW 100144098A TW 100144098 A TW100144098 A TW 100144098A TW I532843 B TWI532843 B TW I532843B
- Authority
- TW
- Taiwan
- Prior art keywords
- nucleic acid
- value
- chromosomal
- cancer
- region
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims description 422
- 201000011510 cancer Diseases 0.000 title claims description 208
- 238000001514 detection method Methods 0.000 title description 24
- 230000002068 genetic effect Effects 0.000 title description 4
- 230000002759 chromosomal effect Effects 0.000 claims description 259
- 102000054766 genetic haplotypes Human genes 0.000 claims description 236
- 238000000034 method Methods 0.000 claims description 162
- 108090000623 proteins and genes Proteins 0.000 claims description 113
- 150000007523 nucleic acids Chemical class 0.000 claims description 109
- 210000000349 chromosome Anatomy 0.000 claims description 101
- 102000039446 nucleic acids Human genes 0.000 claims description 99
- 108020004707 nucleic acids Proteins 0.000 claims description 99
- 230000009977 dual effect Effects 0.000 claims description 90
- 210000001519 tissue Anatomy 0.000 claims description 86
- 230000003321 amplification Effects 0.000 claims description 83
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 83
- 238000009826 distribution Methods 0.000 claims description 77
- 238000012217 deletion Methods 0.000 claims description 76
- 210000004027 cell Anatomy 0.000 claims description 75
- 230000037430 deletion Effects 0.000 claims description 75
- 239000012472 biological sample Substances 0.000 claims description 44
- 230000008859 change Effects 0.000 claims description 23
- 238000012544 monitoring process Methods 0.000 claims description 21
- 230000001747 exhibiting effect Effects 0.000 claims description 17
- 238000012360 testing method Methods 0.000 claims description 14
- 208000006994 Precancerous Conditions Diseases 0.000 claims description 7
- 230000003902 lesion Effects 0.000 claims description 6
- 238000004590 computer program Methods 0.000 claims description 3
- 238000003860 storage Methods 0.000 claims description 3
- 206010061764 Chromosomal deletion Diseases 0.000 claims description 2
- 238000003556 assay Methods 0.000 claims description 2
- 238000000546 chi-square test Methods 0.000 claims description 2
- 238000012353 t test Methods 0.000 claims description 2
- 108020004414 DNA Proteins 0.000 description 247
- 102000053602 DNA Human genes 0.000 description 247
- 239000012634 fragment Substances 0.000 description 161
- 238000004458 analytical method Methods 0.000 description 86
- 239000000523 sample Substances 0.000 description 67
- 238000012163 sequencing technique Methods 0.000 description 56
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 48
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 48
- 230000001186 cumulative effect Effects 0.000 description 37
- 230000000875 corresponding effect Effects 0.000 description 16
- 230000035772 mutation Effects 0.000 description 15
- 238000005259 measurement Methods 0.000 description 12
- 238000012216 screening Methods 0.000 description 11
- 230000035945 sensitivity Effects 0.000 description 11
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 238000007847 digital PCR Methods 0.000 description 9
- 238000005516 engineering process Methods 0.000 description 9
- 239000002773 nucleotide Substances 0.000 description 9
- 125000003729 nucleotide group Chemical group 0.000 description 9
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 8
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 8
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 8
- 238000002271 resection Methods 0.000 description 8
- 210000004881 tumor cell Anatomy 0.000 description 8
- 206010061818 Disease progression Diseases 0.000 description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 description 7
- 238000003745 diagnosis Methods 0.000 description 7
- 238000010586 diagram Methods 0.000 description 7
- 230000005750 disease progression Effects 0.000 description 7
- 238000001356 surgical procedure Methods 0.000 description 7
- 230000004544 DNA amplification Effects 0.000 description 6
- 238000003752 polymerase chain reaction Methods 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 238000013459 approach Methods 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 238000010208 microarray analysis Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 102000054765 polymorphisms of proteins Human genes 0.000 description 5
- 238000003205 genotyping method Methods 0.000 description 4
- 210000001165 lymph node Anatomy 0.000 description 4
- 238000004393 prognosis Methods 0.000 description 4
- 239000013074 reference sample Substances 0.000 description 4
- 238000004904 shortening Methods 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 230000002596 correlated effect Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 238000002493 microarray Methods 0.000 description 3
- 238000003753 real-time PCR Methods 0.000 description 3
- 229920002477 rna polymer Polymers 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 208000031404 Chromosome Aberrations Diseases 0.000 description 2
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 241000700721 Hepatitis B virus Species 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 108700011259 MicroRNAs Proteins 0.000 description 2
- 206010061309 Neoplasm progression Diseases 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 108091027967 Small hairpin RNA Proteins 0.000 description 2
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 2
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000035508 accumulation Effects 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 210000003484 anatomy Anatomy 0.000 description 2
- 238000002869 basic local alignment search tool Methods 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 238000004422 calculation algorithm Methods 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 231100000005 chromosome aberration Toxicity 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 230000002559 cytogenic effect Effects 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000007614 genetic variation Effects 0.000 description 2
- 238000011331 genomic analysis Methods 0.000 description 2
- 201000010536 head and neck cancer Diseases 0.000 description 2
- 208000014829 head and neck neoplasm Diseases 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- 210000003917 human chromosome Anatomy 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 230000008774 maternal effect Effects 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 210000004882 non-tumor cell Anatomy 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 238000010837 poor prognosis Methods 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000003252 repetitive effect Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000002626 targeted therapy Methods 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 230000005751 tumor progression Effects 0.000 description 2
- VGONTNSXDCQUGY-RRKCRQDMSA-N 2'-deoxyinosine Chemical group C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC2=O)=C2N=C1 VGONTNSXDCQUGY-RRKCRQDMSA-N 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 108091032955 Bacterial small RNA Proteins 0.000 description 1
- 206010008263 Cervical dysplasia Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 238000013382 DNA quantification Methods 0.000 description 1
- 108700003861 Dominant Genes Proteins 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 108091007412 Piwi-interacting RNA Proteins 0.000 description 1
- 208000020584 Polyploidy Diseases 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 238000001604 Rao's score test Methods 0.000 description 1
- 240000003705 Senecio vulgaris Species 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 208000036878 aneuploidy Diseases 0.000 description 1
- 231100001075 aneuploidy Toxicity 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 210000002230 centromere Anatomy 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 208000007951 cervical intraepithelial neoplasia Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 108091092240 circulating cell-free DNA Proteins 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000007672 fourth generation sequencing Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000004077 genetic alteration Effects 0.000 description 1
- 230000037442 genomic alteration Effects 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000002998 immunogenetic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 230000005389 magnetism Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 238000001531 micro-dissection Methods 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 210000001819 pancreatic juice Anatomy 0.000 description 1
- 238000009595 pap smear Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 210000004910 pleural fluid Anatomy 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- -1 pro-amines Chemical class 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000011218 segmentation Effects 0.000 description 1
- 238000007841 sequencing by ligation Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000010972 statistical evaluation Methods 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/10—Ploidy or copy number detection
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
- G16B30/10—Sequence alignment; Homology search
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2535/00—Reactions characterised by the assay type for determining the identity of a nucleotide base or a sequence of oligonucleotides
- C12Q2535/122—Massive parallel sequencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2537/00—Reactions characterised by the reaction format or use of a specific feature
- C12Q2537/10—Reactions characterised by the reaction format or use of a specific feature the purpose or use of
- C12Q2537/165—Mathematical modelling, e.g. logarithm, ratio
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2545/00—Reactions characterised by their quantitative nature
- C12Q2545/10—Reactions characterised by their quantitative nature the purpose being quantitative analysis
- C12Q2545/114—Reactions characterised by their quantitative nature the purpose being quantitative analysis involving a quantitation step
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Analytical Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Theoretical Computer Science (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Medical Informatics (AREA)
- Evolutionary Biology (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Algebra (AREA)
- General Physics & Mathematics (AREA)
- Mathematical Analysis (AREA)
- Mathematical Optimization (AREA)
- Mathematical Physics (AREA)
- Pure & Applied Mathematics (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41839110P | 2010-11-30 | 2010-11-30 | |
| US201161529877P | 2011-08-31 | 2011-08-31 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW201307570A TW201307570A (zh) | 2013-02-16 |
| TWI532843B true TWI532843B (zh) | 2016-05-11 |
Family
ID=46171096
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW100144098A TWI532843B (zh) | 2010-11-30 | 2011-11-30 | 與癌症有關之基因或分子變異之檢測 |
| TW105102252A TWI642786B (zh) | 2010-11-30 | 2011-11-30 | 與癌症有關之基因或分子變異之檢測 |
| TW111126139A TW202242133A (zh) | 2010-11-30 | 2011-11-30 | 與癌症有關之基因或分子變異之檢測 |
| TW107129009A TWI719339B (zh) | 2010-11-30 | 2011-11-30 | 與癌症有關之基因或分子變異之檢測 |
| TW110101988A TWI786520B (zh) | 2010-11-30 | 2011-11-30 | 與癌症有關之基因或分子變異之檢測 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW105102252A TWI642786B (zh) | 2010-11-30 | 2011-11-30 | 與癌症有關之基因或分子變異之檢測 |
| TW111126139A TW202242133A (zh) | 2010-11-30 | 2011-11-30 | 與癌症有關之基因或分子變異之檢測 |
| TW107129009A TWI719339B (zh) | 2010-11-30 | 2011-11-30 | 與癌症有關之基因或分子變異之檢測 |
| TW110101988A TWI786520B (zh) | 2010-11-30 | 2011-11-30 | 與癌症有關之基因或分子變異之檢測 |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US8741811B2 (enExample) |
| EP (4) | EP2646579B1 (enExample) |
| JP (5) | JP6196157B2 (enExample) |
| KR (6) | KR102333664B1 (enExample) |
| CN (4) | CN108899091B (enExample) |
| AU (1) | AU2011335891B2 (enExample) |
| BR (1) | BR112013013421A2 (enExample) |
| CA (1) | CA2817370C (enExample) |
| DK (2) | DK2646579T3 (enExample) |
| EA (1) | EA038374B1 (enExample) |
| IL (3) | IL226272A (enExample) |
| MX (3) | MX349568B (enExample) |
| MY (1) | MY169852A (enExample) |
| NZ (1) | NZ611599A (enExample) |
| SG (3) | SG190344A1 (enExample) |
| TW (5) | TWI532843B (enExample) |
| WO (1) | WO2012071621A1 (enExample) |
| ZA (1) | ZA201304625B (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI669618B (zh) * | 2017-11-24 | 2019-08-21 | 南韓商韓國美迪基因科技有限公司 | 預測疾病的方法及裝置以及計算每種疾病發生風險的加權分數的方法 |
Families Citing this family (153)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11111544B2 (en) | 2005-07-29 | 2021-09-07 | Natera, Inc. | System and method for cleaning noisy genetic data and determining chromosome copy number |
| US10083273B2 (en) | 2005-07-29 | 2018-09-25 | Natera, Inc. | System and method for cleaning noisy genetic data and determining chromosome copy number |
| US11111543B2 (en) | 2005-07-29 | 2021-09-07 | Natera, Inc. | System and method for cleaning noisy genetic data and determining chromosome copy number |
| US9424392B2 (en) | 2005-11-26 | 2016-08-23 | Natera, Inc. | System and method for cleaning noisy genetic data from target individuals using genetic data from genetically related individuals |
| US10081839B2 (en) | 2005-07-29 | 2018-09-25 | Natera, Inc | System and method for cleaning noisy genetic data and determining chromosome copy number |
| KR102561664B1 (ko) | 2007-07-23 | 2023-07-28 | 더 차이니즈 유니버시티 오브 홍콩 | 대규모 병렬 게놈 서열분석을 이용한 태아 염색체 이수성의 진단 방법 |
| AU2009279734A1 (en) | 2008-08-04 | 2010-02-11 | Natera, Inc. | Methods for allele calling and ploidy calling |
| CN102597266A (zh) | 2009-09-30 | 2012-07-18 | 纳特拉公司 | 无创性产前倍性调用的方法 |
| PL2366031T3 (pl) | 2010-01-19 | 2015-08-31 | Verinata Health Inc | Metody sekwencjonowania w diagnostyce prenatalnej |
| US10388403B2 (en) | 2010-01-19 | 2019-08-20 | Verinata Health, Inc. | Analyzing copy number variation in the detection of cancer |
| AU2011207561B2 (en) | 2010-01-19 | 2014-02-20 | Verinata Health, Inc. | Partition defined detection methods |
| US20120010085A1 (en) | 2010-01-19 | 2012-01-12 | Rava Richard P | Methods for determining fraction of fetal nucleic acids in maternal samples |
| US20120100548A1 (en) | 2010-10-26 | 2012-04-26 | Verinata Health, Inc. | Method for determining copy number variations |
| US9260745B2 (en) | 2010-01-19 | 2016-02-16 | Verinata Health, Inc. | Detecting and classifying copy number variation |
| US9323888B2 (en) | 2010-01-19 | 2016-04-26 | Verinata Health, Inc. | Detecting and classifying copy number variation |
| CA2786564A1 (en) | 2010-01-19 | 2011-07-28 | Verinata Health, Inc. | Identification of polymorphic sequences in mixtures of genomic dna by whole genome sequencing |
| US11326208B2 (en) | 2010-05-18 | 2022-05-10 | Natera, Inc. | Methods for nested PCR amplification of cell-free DNA |
| US8825412B2 (en) | 2010-05-18 | 2014-09-02 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
| US20190010543A1 (en) | 2010-05-18 | 2019-01-10 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| US9677118B2 (en) | 2014-04-21 | 2017-06-13 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| US11339429B2 (en) | 2010-05-18 | 2022-05-24 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
| US11332785B2 (en) | 2010-05-18 | 2022-05-17 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
| US11939634B2 (en) | 2010-05-18 | 2024-03-26 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| US12221653B2 (en) | 2010-05-18 | 2025-02-11 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| US11332793B2 (en) | 2010-05-18 | 2022-05-17 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| US12152275B2 (en) | 2010-05-18 | 2024-11-26 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
| US11408031B2 (en) | 2010-05-18 | 2022-08-09 | Natera, Inc. | Methods for non-invasive prenatal paternity testing |
| US10316362B2 (en) | 2010-05-18 | 2019-06-11 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| US11322224B2 (en) | 2010-05-18 | 2022-05-03 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
| EP2646579B1 (en) | 2010-11-30 | 2017-06-14 | The Chinese University Of Hong Kong | Detection of genetic or molecular aberrations associated with cancer |
| EP2656263B1 (en) | 2010-12-22 | 2019-11-06 | Natera, Inc. | Methods for non-invasive prenatal paternity testing |
| EP2673380B1 (en) * | 2011-02-09 | 2018-12-12 | Bio-Rad Laboratories, Inc. | Analysis of nucleic acids |
| RU2671980C2 (ru) | 2011-02-09 | 2018-11-08 | Натера, Инк. | Способы неинвазивного пренатального установления плоидности |
| ES2806728T3 (es) | 2011-04-12 | 2021-02-18 | Verinata Health Inc | Resolución de fracciones de genoma usando recuentos de polimorfismos |
| PL3246416T3 (pl) | 2011-04-15 | 2024-09-30 | The Johns Hopkins University | Bezpieczny system sekwencjonowania |
| US9411937B2 (en) * | 2011-04-15 | 2016-08-09 | Verinata Health, Inc. | Detecting and classifying copy number variation |
| US9605313B2 (en) | 2012-03-02 | 2017-03-28 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
| US9892230B2 (en) * | 2012-03-08 | 2018-02-13 | The Chinese University Of Hong Kong | Size-based analysis of fetal or tumor DNA fraction in plasma |
| CA2867293C (en) | 2012-03-13 | 2020-09-01 | Abhijit Ajit PATEL | Measurement of nucleic acid variants using highly-multiplexed error-suppressed deep sequencing |
| US11261494B2 (en) * | 2012-06-21 | 2022-03-01 | The Chinese University Of Hong Kong | Method of measuring a fractional concentration of tumor DNA |
| EP2877594B1 (en) * | 2012-07-20 | 2019-12-04 | Verinata Health, Inc. | Detecting and classifying copy number variation in a fetal genome |
| US20140100126A1 (en) | 2012-08-17 | 2014-04-10 | Natera, Inc. | Method for Non-Invasive Prenatal Testing Using Parental Mosaicism Data |
| SG10202000486VA (en) | 2012-09-04 | 2020-03-30 | Guardant Health Inc | Systems and methods to detect rare mutations and copy number variation |
| US11913065B2 (en) | 2012-09-04 | 2024-02-27 | Guardent Health, Inc. | Systems and methods to detect rare mutations and copy number variation |
| US20160040229A1 (en) * | 2013-08-16 | 2016-02-11 | Guardant Health, Inc. | Systems and methods to detect rare mutations and copy number variation |
| US10876152B2 (en) | 2012-09-04 | 2020-12-29 | Guardant Health, Inc. | Systems and methods to detect rare mutations and copy number variation |
| US9732390B2 (en) | 2012-09-20 | 2017-08-15 | The Chinese University Of Hong Kong | Non-invasive determination of methylome of fetus or tumor from plasma |
| US10706957B2 (en) | 2012-09-20 | 2020-07-07 | The Chinese University Of Hong Kong | Non-invasive determination of methylome of tumor from plasma |
| EP2898100B9 (en) | 2012-09-20 | 2023-08-02 | The Chinese University Of Hong Kong | Non-invasive determination of methylome of fetus or tumor from plasma |
| US10482994B2 (en) | 2012-10-04 | 2019-11-19 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
| CA2889937C (en) | 2012-10-29 | 2020-12-29 | The Johns Hopkins University | Papanicolaou test for ovarian and endometrial cancers |
| EP3561072A1 (en) | 2012-12-10 | 2019-10-30 | Resolution Bioscience, Inc. | Methods for targeted genomic analysis |
| US10643738B2 (en) * | 2013-01-10 | 2020-05-05 | The Chinese University Of Hong Kong | Noninvasive prenatal molecular karyotyping from maternal plasma |
| EP3597774A1 (en) | 2013-03-13 | 2020-01-22 | Sequenom, Inc. | Primers for dna methylation analysis |
| EP4253558B1 (en) * | 2013-03-15 | 2025-07-02 | The Board of Trustees of the Leland Stanford Junior University | Identification and use of circulating nucleic acid tumor markers |
| CN112575075B (zh) | 2013-05-24 | 2025-09-16 | 塞昆纳姆股份有限公司 | 遗传变异的非侵入性评估方法和过程 |
| WO2015013681A1 (en) | 2013-07-25 | 2015-01-29 | Bio-Rad Laboratories, Inc. | Genetic assays |
| US10577655B2 (en) | 2013-09-27 | 2020-03-03 | Natera, Inc. | Cell free DNA diagnostic testing standards |
| US9499870B2 (en) | 2013-09-27 | 2016-11-22 | Natera, Inc. | Cell free DNA diagnostic testing standards |
| US10262755B2 (en) | 2014-04-21 | 2019-04-16 | Natera, Inc. | Detecting cancer mutations and aneuploidy in chromosomal segments |
| US10851414B2 (en) * | 2013-10-18 | 2020-12-01 | Good Start Genetics, Inc. | Methods for determining carrier status |
| WO2015061359A1 (en) * | 2013-10-21 | 2015-04-30 | Verinata Health, Inc. | Method for improving the sensitivity of detection in determining copy number variations |
| SG10201804519RA (en) | 2013-12-28 | 2018-07-30 | Guardant Health Inc | Methods and systems for detecting genetic variants |
| WO2015138774A1 (en) | 2014-03-13 | 2015-09-17 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
| WO2015164432A1 (en) * | 2014-04-21 | 2015-10-29 | Natera, Inc. | Detecting mutations and ploidy in chromosomal segments |
| US12492429B2 (en) | 2014-04-21 | 2025-12-09 | Natera, Inc. | Detecting mutations and ploidy in chromosomal segments |
| JP6659575B2 (ja) | 2014-04-21 | 2020-03-04 | ナテラ， インコーポレイテッド | 変異の検出および染色体分節の倍数性 |
| AU2015266665C1 (en) | 2014-05-30 | 2021-12-23 | Verinata Health, Inc. | Detecting fetal sub-chromosomal aneuploidies and copy number variations |
| US20180173845A1 (en) | 2014-06-05 | 2018-06-21 | Natera, Inc. | Systems and Methods for Detection of Aneuploidy |
| HUE056267T2 (hu) | 2014-07-18 | 2022-02-28 | Univ Hong Kong Chinese | DNS-keverékek szöveteinek metilációs mintázatelemzése |
| JP2017522908A (ja) | 2014-07-25 | 2017-08-17 | ユニヴァーシティ オブ ワシントン | セルフリーｄｎａを生じる組織及び／又は細胞タイプを決定する方法、並びにそれを用いて疾患又は異常を識別する方法 |
| EP3760739B1 (en) * | 2014-07-30 | 2025-09-03 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
| US20160048608A1 (en) | 2014-08-15 | 2016-02-18 | Good Start Genetics, Inc. | Systems and methods for genetic analysis |
| US20160053301A1 (en) | 2014-08-22 | 2016-02-25 | Clearfork Bioscience, Inc. | Methods for quantitative genetic analysis of cell free dna |
| EP3230469B1 (en) | 2014-12-12 | 2019-04-03 | Verinata Health, Inc. | Using cell-free dna fragment size to determine copy number variations |
| US11242559B2 (en) | 2015-01-13 | 2022-02-08 | The Chinese University Of Hong Kong | Method of nuclear DNA and mitochondrial DNA analysis |
| US10364467B2 (en) | 2015-01-13 | 2019-07-30 | The Chinese University Of Hong Kong | Using size and number aberrations in plasma DNA for detecting cancer |
| US10319463B2 (en) * | 2015-01-23 | 2019-06-11 | The Chinese University Of Hong Kong | Combined size- and count-based analysis of maternal plasma for detection of fetal subchromosomal aberrations |
| DK3256605T3 (da) | 2015-02-10 | 2022-03-14 | Univ Hong Kong Chinese | Påvisning af mutationer til cancerscreening og føtal analyse |
| US10424396B2 (en) * | 2015-03-27 | 2019-09-24 | Sentieon Inc. | Computation pipeline of location-dependent variant calls |
| SG11201708301TA (en) * | 2015-04-10 | 2017-11-29 | Social Welfare Organization Saiseikai Imp Gift Foundation Inc | Method for discriminating symptom of hepatic disease |
| EP4428863A3 (en) | 2015-05-11 | 2024-12-11 | Natera, Inc. | Methods and compositions for determining ploidy |
| EP3739061B1 (en) | 2015-07-20 | 2022-03-23 | The Chinese University Of Hong Kong | Methylation pattern analysis of haplotypes in tissues in dna mixture |
| ES2960201T3 (es) | 2015-07-23 | 2024-03-01 | Univ Hong Kong Chinese | Análisis de los patrones de fragmentación del ADN acelular |
| JP6675164B2 (ja) * | 2015-07-28 | 2020-04-01 | 株式会社理研ジェネシス | 変異判定方法、変異判定プログラムおよび記録媒体 |
| US11286531B2 (en) | 2015-08-11 | 2022-03-29 | The Johns Hopkins University | Assaying ovarian cyst fluid |
| MY188348A (en) | 2015-08-12 | 2021-12-02 | Univ Hong Kong Chinese | Single-molecule sequencing of plasma dna |
| CA3004435A1 (en) | 2015-11-11 | 2017-05-18 | Resolution Bioscience, Inc. | High efficiency construction of dna libraries |
| WO2017106768A1 (en) | 2015-12-17 | 2017-06-22 | Guardant Health, Inc. | Methods to determine tumor gene copy number by analysis of cell-free dna |
| US10095831B2 (en) | 2016-02-03 | 2018-10-09 | Verinata Health, Inc. | Using cell-free DNA fragment size to determine copy number variations |
| AU2017237187B2 (en) | 2016-03-24 | 2022-12-08 | Xzom, Inc. | Disposable fluidic cartridge and components |
| WO2017181202A2 (en) | 2016-04-15 | 2017-10-19 | Natera, Inc. | Methods for lung cancer detection |
| IL303115B2 (en) | 2016-05-30 | 2025-09-01 | Univ Hong Kong Chinese | Detection of hematological disorders using cell-free DNA in blood |
| CA3030890A1 (en) | 2016-07-27 | 2018-02-01 | Sequenom, Inc. | Genetic copy number alteration classifications |
| SG11201901371XA (en) | 2016-08-25 | 2019-03-28 | Resolution Bioscience Inc | Methods for the detection of genomic copy changes in dna samples |
| CA3037366A1 (en) * | 2016-09-29 | 2018-04-05 | Myriad Women's Health, Inc. | Noninvasive prenatal screening using dynamic iterative depth optimization |
| US11485996B2 (en) | 2016-10-04 | 2022-11-01 | Natera, Inc. | Methods for characterizing copy number variation using proximity-litigation sequencing |
| CA3041647A1 (en) | 2016-10-24 | 2018-05-03 | The Chinese University Of Hong Kong | Methods and systems for tumor detection |
| GB201618485D0 (en) | 2016-11-02 | 2016-12-14 | Ucl Business Plc | Method of detecting tumour recurrence |
| JP2020503003A (ja) | 2016-11-30 | 2020-01-30 | ザ チャイニーズ ユニバーシティ オブ ホンコン | 尿および他のサンプルにおける無細胞ｄｎａの分析 |
| US10011870B2 (en) | 2016-12-07 | 2018-07-03 | Natera, Inc. | Compositions and methods for identifying nucleic acid molecules |
| JP7237003B2 (ja) | 2017-01-24 | 2023-03-10 | セクエノム， インコーポレイテッド | 遺伝子片の評価のための方法およびプロセス |
| US10633713B2 (en) | 2017-01-25 | 2020-04-28 | The Chinese University Of Hong Kong | Diagnostic applications using nucleic acid fragments |
| AU2018225348A1 (en) | 2017-02-21 | 2019-07-18 | Natera, Inc. | Compositions, methods, and kits for isolating nucleic acids |
| IL269202B2 (en) | 2017-03-17 | 2025-08-01 | Sequenom Inc | Methods and processes for assessment of genetic mosaicism |
| US11342047B2 (en) | 2017-04-21 | 2022-05-24 | Illumina, Inc. | Using cell-free DNA fragment size to detect tumor-associated variant |
| CA3062585A1 (en) | 2017-05-08 | 2018-11-15 | Biological Dynamics, Inc. | Methods and systems for analyte information processing |
| KR102145417B1 (ko) * | 2017-05-24 | 2020-08-19 | 지니너스 주식회사 | 무세포 핵산으로부터 수득된 서열 분석 데이터에 대한 배경 대립인자의 빈도 분포를 생성하는 방법 및 이를 이용하여 무세포 핵산으로부터 변이를 검출하는 방법 |
| SG11201911642SA (en) * | 2017-06-08 | 2020-01-30 | Nantomics Llc | An integrative panomic approach to pharmacogenomics screening |
| DK3658684T3 (da) | 2017-07-26 | 2023-10-09 | Univ Hong Kong Chinese | Forbedring af cancerscreening ved hjælp af cellefrie, virale nukleinsyrer |
| WO2019067092A1 (en) | 2017-08-07 | 2019-04-04 | The Johns Hopkins University | METHODS AND SUBSTANCES FOR THE EVALUATION AND TREATMENT OF CANCER |
| CN110021355B (zh) * | 2017-09-22 | 2021-05-04 | 深圳华大生命科学研究院 | 二倍体基因组测序片段的单倍体分型和变异检测方法和装置 |
| US11168356B2 (en) | 2017-11-02 | 2021-11-09 | The Chinese University Of Hong Kong | Using nucleic acid size range for noninvasive cancer detection |
| CA3085933A1 (en) | 2017-12-14 | 2019-06-20 | Tai Diagnostics, Inc. | Assessing graft suitability for transplantation |
| JP2021509266A (ja) * | 2017-12-19 | 2021-03-25 | バイオロジカル ダイナミクス，インク． | 無細胞ｄｎａ断片を検出および定量化するための方法とデバイス |
| AU2018388641B2 (en) | 2017-12-19 | 2023-09-07 | Xzom, Inc. | Methods and devices for detection of multiple analytes from a biological sample |
| US12398389B2 (en) | 2018-02-15 | 2025-08-26 | Natera, Inc. | Methods for isolating nucleic acids with size selection |
| TW202434742A (zh) | 2018-03-13 | 2024-09-01 | 美商格瑞爾有限責任公司 | 異常片段偵測及分類 |
| CA3093971A1 (en) | 2018-03-15 | 2019-09-19 | Grail, Inc. | Tissue-specific methylation marker |
| US12154661B2 (en) * | 2018-03-22 | 2024-11-26 | The Regents Of The University Of Michigan | Method and apparatus for analysis of chromatin interaction data |
| CN117065932A (zh) | 2018-04-02 | 2023-11-17 | 生物动力学公司 | 介电材料 |
| EP3776555A2 (en) | 2018-04-13 | 2021-02-17 | Grail, Inc. | Multi-assay prediction model for cancer detection |
| AU2019251504B2 (en) | 2018-04-14 | 2025-09-25 | Natera, Inc. | Methods for cancer detection and monitoring by means of personalized detection of circulating tumor DNA |
| EP3788172B1 (en) | 2018-05-03 | 2025-04-02 | The Chinese University Of Hong Kong | Size-tagged preferred ends and orientation-aware analysis for measuring properties of cell-free mixtures |
| EP3801623A4 (en) | 2018-06-01 | 2022-03-23 | Grail, LLC | Convolutional neural network systems and methods for data classification |
| TW202013385A (zh) | 2018-06-07 | 2020-04-01 | 美商河谷控股Ｉｐ有限責任公司 | 基於差異的基因組之辨識分數 |
| CN112739828B (zh) * | 2018-06-11 | 2024-04-09 | 深圳华大生命科学研究院 | 确定待测样本类型的方法及系统 |
| US12234509B2 (en) | 2018-07-03 | 2025-02-25 | Natera, Inc. | Methods for detection of donor-derived cell-free DNA |
| AU2019356497B2 (en) * | 2018-10-08 | 2025-06-26 | Freenome Holdings, Inc. | Transcription factor profiling |
| US11581062B2 (en) | 2018-12-10 | 2023-02-14 | Grail, Llc | Systems and methods for classifying patients with respect to multiple cancer classes |
| KR20210113237A (ko) | 2018-12-19 | 2021-09-15 | 더 차이니즈 유니버시티 오브 홍콩 | 무 세포 dna 말단 특성 |
| US12234514B2 (en) | 2018-12-21 | 2025-02-25 | Grail, Inc. | Source of origin deconvolution based on methylation fragments in cell-free DNA samples |
| WO2020127629A1 (en) * | 2018-12-21 | 2020-06-25 | F. Hoffmann-La Roche Ag | Identification of global sequence features in whole genome sequence data from circulating nucelic acid |
| US11929148B2 (en) | 2019-03-13 | 2024-03-12 | Grail, Llc | Systems and methods for enriching for cancer-derived fragments using fragment size |
| US12098429B2 (en) | 2019-03-25 | 2024-09-24 | The Chinese University Of Hong Kong | Determining linear and circular forms of circulating nucleic acids |
| CA3128379A1 (en) * | 2019-04-02 | 2020-10-08 | Grail, Inc. | Stratification of risk of virus associated cancers |
| US12497662B2 (en) | 2019-04-16 | 2025-12-16 | Grail, Inc. | Systems and methods for tumor fraction estimation from small variants |
| JP7518097B2 (ja) * | 2019-05-10 | 2024-07-17 | バイエル・コシューマー・ケア・アクチェンゲゼルシャフト | Ｎｔｒｋの発癌性融合を示す候補となる徴候の識別 |
| EP3980559A1 (en) | 2019-06-06 | 2022-04-13 | Natera, Inc. | Methods for detecting immune cell dna and monitoring immune system |
| CN110825819A (zh) * | 2019-09-24 | 2020-02-21 | 昆明理工大学 | 一种处理有缺失值和不平衡非小细胞肺癌数据的二分类方法 |
| CA3158101A1 (en) | 2019-11-27 | 2021-06-03 | M. Cyrus MAHER | Systems and methods for evaluating longitudinal biological feature data |
| US20220073977A1 (en) | 2020-02-14 | 2022-03-10 | The Johns Hopkins University | Methods and materials for assessing nucleic acids |
| US11475981B2 (en) | 2020-02-18 | 2022-10-18 | Tempus Labs, Inc. | Methods and systems for dynamic variant thresholding in a liquid biopsy assay |
| US11211147B2 (en) | 2020-02-18 | 2021-12-28 | Tempus Labs, Inc. | Estimation of circulating tumor fraction using off-target reads of targeted-panel sequencing |
| US11211144B2 (en) | 2020-02-18 | 2021-12-28 | Tempus Labs, Inc. | Methods and systems for refining copy number variation in a liquid biopsy assay |
| CN114093417B (zh) * | 2021-11-23 | 2022-10-04 | 深圳吉因加信息科技有限公司 | 一种鉴定染色体臂杂合性缺失的方法和装置 |
| CN115220623B (zh) * | 2021-12-17 | 2023-12-05 | 深圳市瑞图生物技术有限公司 | 染色体图像分析方法、设备及存储介质 |
| JP2025506435A (ja) | 2022-02-07 | 2025-03-11 | センター フォー ノヴォスティクス | メチル化及び疾患を測定するための断片化 |
| CN114525341A (zh) * | 2022-02-24 | 2022-05-24 | 苏州宏元生物科技有限公司 | 一种同时检测肺癌和肺部感染的试剂盒 |
| US20250382674A1 (en) | 2022-06-29 | 2025-12-18 | Raman Govindarajan | Method for detecting cancer susceptibility, early detection and predicting cancer behaviour |
| CN114898802B (zh) * | 2022-07-14 | 2022-09-30 | 臻和(北京)生物科技有限公司 | 基于血浆游离dna甲基化测序数据的末端序列频率分布特征确定方法、评价方法及装置 |
| EP4634407A1 (en) * | 2022-12-12 | 2025-10-22 | Flagship Pioneering Innovations VI, LLC | Phased sequencing information from circulating tumor dna |
| WO2024203348A1 (ja) * | 2023-03-31 | 2024-10-03 | ソニーグループ株式会社 | 腫瘍の解析方法、腫瘍の解析システム、及び腫瘍の解析データ生成方法 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0669990A1 (en) * | 1992-11-13 | 1995-09-06 | California Institute Of Biological Research | Identification of neoplasms by detection of genetic insertions and deletions |
| CH686982A5 (fr) | 1993-12-16 | 1996-08-15 | Maurice Stroun | Méthode pour le diagnostic de cancers. |
| EP0956365A4 (en) * | 1996-08-28 | 2004-08-25 | Univ Johns Hopkins Med | METHOD FOR DETECTING CELL PROLIFERATIVE DEREGULATIONS |
| EP1158055A1 (fr) | 2000-05-26 | 2001-11-28 | Xu Qi University of Teaxs Laboratoire de Leucémie Chen | Méthode pour le diagnostic de cancers |
| US20030219802A1 (en) * | 2002-03-08 | 2003-11-27 | The Regents Of The University Of Michigan | Diagnosis and treatment of osteosarcoma |
| AU2003291481A1 (en) * | 2002-11-11 | 2004-06-03 | Affymetrix, Inc. | Methods for identifying dna copy number changes |
| US7704687B2 (en) | 2002-11-15 | 2010-04-27 | The Johns Hopkins University | Digital karyotyping |
| CA2544178A1 (en) | 2003-10-30 | 2005-05-19 | Tufts-New England Medical Center | Prenatal diagnosis using cell-free fetal dna in amniotic fluid |
| EP1531183A1 (en) | 2003-11-14 | 2005-05-18 | bioMérieux BV | Method for amplification of RNA sequences |
| JP2006094760A (ja) * | 2004-09-29 | 2006-04-13 | Canon Inc | 細胞のスクリーニング方法および口腔癌細胞検出方法 |
| DE602005009324D1 (de) | 2005-04-06 | 2008-10-09 | Maurice Stroun | Methode zur Krebsdiagnose mittels Nachweis von DNA und RNA im Kreislauf |
| CA2633339C (en) * | 2005-12-14 | 2019-03-19 | Cold Spring Harbor Laboratory | Methods for assessing probabilistic measures of clinical outcome using genomic profiling |
| EP1974056A2 (en) * | 2005-12-14 | 2008-10-01 | Michael H. Wigler | Use of roma for characterizing genomic rearrangements |
| FI20061136A0 (fi) * | 2006-12-19 | 2006-12-19 | Sakari Knuutila | Seulontamenetelmä |
| CN100533120C (zh) * | 2007-03-24 | 2009-08-26 | 辽宁师范大学 | 多色荧光复合扩增11个肺癌易感性相关snp位点试剂盒 |
| WO2008156827A2 (en) * | 2007-06-20 | 2008-12-24 | Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Molecular grading methods for ductal carcinoma in situ |
| US12180549B2 (en) * | 2007-07-23 | 2024-12-31 | The Chinese University Of Hong Kong | Diagnosing fetal chromosomal aneuploidy using genomic sequencing |
| KR102561664B1 (ko) | 2007-07-23 | 2023-07-28 | 더 차이니즈 유니버시티 오브 홍콩 | 대규모 병렬 게놈 서열분석을 이용한 태아 염색체 이수성의 진단 방법 |
| US8093063B2 (en) | 2007-11-29 | 2012-01-10 | Quest Diagnostics Investments Incorporated | Assay for detecting genetic abnormalities in genomic nucleic acids |
| US20100041048A1 (en) * | 2008-07-31 | 2010-02-18 | The Johns Hopkins University | Circulating Mutant DNA to Assess Tumor Dynamics |
| GB2483810B (en) * | 2008-11-07 | 2012-09-05 | Sequenta Inc | Methods for correlating clonotypes with diseases in a population |
| US20100136560A1 (en) | 2008-12-02 | 2010-06-03 | The Johns Hopkins University | Integrated Analyses of Breast and Colorectal Cancers |
| WO2010070366A1 (en) * | 2008-12-15 | 2010-06-24 | Debreceni Egyetem | Cytometric method for the comparative analysis of the length of pcr products and uses of this method |
| CN104531837A (zh) | 2008-12-22 | 2015-04-22 | 赛卢拉有限公司 | 检测等位基因、基因组和转录物组的方法和基因型分析谱 |
| LT3783110T (lt) | 2009-11-05 | 2023-01-25 | The Chinese University Of Hong Kong | Vaisiaus genomo analizė iš motinos biologinio mėginio |
| US8620593B2 (en) | 2009-11-06 | 2013-12-31 | The Chinese University Of Hong Kong | Size-based genomic analysis |
| CA2786564A1 (en) | 2010-01-19 | 2011-07-28 | Verinata Health, Inc. | Identification of polymorphic sequences in mixtures of genomic dna by whole genome sequencing |
| PL2366031T3 (pl) | 2010-01-19 | 2015-08-31 | Verinata Health Inc | Metody sekwencjonowania w diagnostyce prenatalnej |
| WO2011103236A2 (en) | 2010-02-18 | 2011-08-25 | The Johns Hopkins University | Personalized tumor biomarkers |
| EP2558854B1 (en) * | 2010-04-16 | 2018-10-10 | Chronix Biomedical | Breast cancer associated circulating nucleic acid biomarkers |
| CA2797645C (en) * | 2010-05-25 | 2020-09-22 | The Regents Of The University Of California | Bambam: parallel comparative analysis of high-throughput sequencing data |
| US20120034603A1 (en) * | 2010-08-06 | 2012-02-09 | Tandem Diagnostics, Inc. | Ligation-based detection of genetic variants |
| EP2646579B1 (en) | 2010-11-30 | 2017-06-14 | The Chinese University Of Hong Kong | Detection of genetic or molecular aberrations associated with cancer |
-
2011
- 2011-11-30 EP EP11845367.9A patent/EP2646579B1/en active Active
- 2011-11-30 EP EP17168020.0A patent/EP3243910B1/en not_active Revoked
- 2011-11-30 SG SG2013038773A patent/SG190344A1/en unknown
- 2011-11-30 DK DK11845367.9T patent/DK2646579T3/en active
- 2011-11-30 EA EA201300649A patent/EA038374B1/ru unknown
- 2011-11-30 KR KR1020207033400A patent/KR102333664B1/ko active Active
- 2011-11-30 TW TW100144098A patent/TWI532843B/zh active
- 2011-11-30 NZ NZ611599A patent/NZ611599A/en unknown
- 2011-11-30 DK DK17168020.0T patent/DK3243910T3/da active
- 2011-11-30 CN CN201810817319.1A patent/CN108899091B/zh active Active
- 2011-11-30 SG SG10202008532PA patent/SG10202008532PA/en unknown
- 2011-11-30 CN CN202210291074.XA patent/CN114678128A/zh active Pending
- 2011-11-30 WO PCT/AU2011/001562 patent/WO2012071621A1/en not_active Ceased
- 2011-11-30 KR KR1020187023415A patent/KR102040307B1/ko active Active
- 2011-11-30 MX MX2013006075A patent/MX349568B/es active IP Right Grant
- 2011-11-30 SG SG10201509766YA patent/SG10201509766YA/en unknown
- 2011-11-30 JP JP2013541152A patent/JP6196157B2/ja active Active
- 2011-11-30 KR KR1020237001326A patent/KR102723107B1/ko active Active
- 2011-11-30 US US13/308,473 patent/US8741811B2/en active Active
- 2011-11-30 AU AU2011335891A patent/AU2011335891B2/en active Active
- 2011-11-30 KR KR1020137016780A patent/KR101891847B1/ko active Active
- 2011-11-30 KR KR1020217038741A patent/KR102489749B1/ko active Active
- 2011-11-30 MX MX2017009968A patent/MX370249B/es unknown
- 2011-11-30 TW TW105102252A patent/TWI642786B/zh active
- 2011-11-30 CN CN201510615900.1A patent/CN105243295B/zh active Active
- 2011-11-30 MY MYPI2013001960A patent/MY169852A/en unknown
- 2011-11-30 EP EP23190213.1A patent/EP4269623A3/en active Pending
- 2011-11-30 TW TW111126139A patent/TW202242133A/zh unknown
- 2011-11-30 CN CN201180066175.7A patent/CN103403182B/zh active Active
- 2011-11-30 EP EP19206273.5A patent/EP3640346A1/en active Pending
- 2011-11-30 BR BR112013013421A patent/BR112013013421A2/pt not_active Application Discontinuation
- 2011-11-30 TW TW107129009A patent/TWI719339B/zh active
- 2011-11-30 CA CA2817370A patent/CA2817370C/en active Active
- 2011-11-30 KR KR1020197032092A patent/KR102185244B1/ko active Active
- 2011-11-30 TW TW110101988A patent/TWI786520B/zh active
-
2013
- 2013-05-09 IL IL226272A patent/IL226272A/en active IP Right Grant
- 2013-05-30 MX MX2019014657A patent/MX2019014657A/es unknown
- 2013-06-21 ZA ZA2013/04625A patent/ZA201304625B/en unknown
-
2014
- 2014-04-17 US US14/255,415 patent/US9965585B2/en active Active
-
2016
- 2016-01-28 IL IL243823A patent/IL243823A/en active IP Right Grant
-
2017
- 2017-03-05 IL IL250931A patent/IL250931A0/en unknown
- 2017-04-19 US US15/491,507 patent/US12002544B2/en active Active
- 2017-08-08 JP JP2017153310A patent/JP6487504B2/ja active Active
-
2019
- 2019-02-20 JP JP2019028674A patent/JP6931013B2/ja active Active
-
2021
- 2021-08-12 JP JP2021131762A patent/JP7351537B2/ja active Active
-
2023
- 2023-09-07 JP JP2023145456A patent/JP2023179458A/ja active Pending
-
2024
- 2024-05-24 US US18/674,702 patent/US20250006299A1/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI669618B (zh) * | 2017-11-24 | 2019-08-21 | 南韓商韓國美迪基因科技有限公司 | 預測疾病的方法及裝置以及計算每種疾病發生風險的加權分數的方法 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI532843B (zh) | 與癌症有關之基因或分子變異之檢測 | |
| AU2022202130A1 (en) | Detection of genetic or molecular aberrations associated with cancer | |
| HK40074975A (en) | Detection of genetic or molecular aberrations associated with cancer | |
| HK1260290B (en) | Detection of genetic or molecular aberrations associated with cancer | |
| HK1260290A1 (en) | Detection of genetic or molecular aberrations associated with cancer | |
| HK1217553B (en) | Detection of genetic or molecular aberrations associated with cancer | |
| HK1240278B (en) | Determination of progress of chromosomal aberrations in an organism | |
| HK1240278A1 (en) | Determination of progress of chromosomal aberrations in an organism | |
| HK1190435B (en) | Detection of genetic or molecular aberrations associated with cancer | |
| HK1190435A (en) | Detection of genetic or molecular aberrations associated with cancer |